Adicet Bio (NASDAQ:ACET – Get Rating) and BetterLife Pharma (OTCMKTS:BETRF – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
This table compares Adicet Bio and BetterLife Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Adicet Bio and BetterLife Pharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adicet Bio||$9.73 million||33.95||-$62.00 million||($1.46)||-5.28|
|BetterLife Pharma||N/A||N/A||-$9.71 million||($0.11)||-0.61|
This is a summary of current ratings for Adicet Bio and BetterLife Pharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Adicet Bio currently has a consensus target price of $27.83, suggesting a potential upside of 261.00%. Given Adicet Bio’s higher probable upside, research analysts clearly believe Adicet Bio is more favorable than BetterLife Pharma.
Volatility & Risk
Adicet Bio has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Comparatively, BetterLife Pharma has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Adicet Bio beats BetterLife Pharma on 5 of the 9 factors compared between the two stocks.
About Adicet Bio
Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
About BetterLife Pharma
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.